Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEfficacy and Safety of the Combination of Docetaxel with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets, 10/23/09
Chiuri VE et al. – Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells.
Related Articles
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Relevance Score: 93%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 91%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 88%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment
Annals of Surgical Oncology, 12/15/09
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
Targeting cancer with phosphodiesterase inhibitors
Expert Opinion on Investigational Drugs, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor